Biodesix, Inc. (NASDAQ:BDSX) CFO Sells $22,690.88 in Stock

Biodesix, Inc. (NASDAQ:BDSX) CFO Robin Harper Cowie sold 24,664 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $22,690.88. Following the sale, the chief financial officer now owns 246,460 shares of the company’s stock, valued at approximately $226,743.20. This represents a 9.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Biodesix Stock Down 1.1 %

Shares of NASDAQ BDSX traded down $0.01 during trading on Wednesday, reaching $0.94. 170,859 shares of the stock were exchanged, compared to its average volume of 460,809. The company has a market capitalization of $136.74 million, a price-to-earnings ratio of -2.41 and a beta of 1.06. The business’s 50-day moving average price is $1.26 and its 200 day moving average price is $1.49. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. Biodesix, Inc. has a twelve month low of $0.86 and a twelve month high of $2.04.

Institutional Trading of Biodesix

Several institutional investors have recently added to or reduced their stakes in BDSX. Geode Capital Management LLC grew its position in shares of Biodesix by 2.8% during the fourth quarter. Geode Capital Management LLC now owns 827,199 shares of the company’s stock worth $1,266,000 after acquiring an additional 22,623 shares during the last quarter. AIGH Capital Management LLC grew its position in shares of Biodesix by 8.8% during the fourth quarter. AIGH Capital Management LLC now owns 6,179,812 shares of the company’s stock worth $9,455,000 after acquiring an additional 500,000 shares during the last quarter. Perkins Capital Management Inc. grew its position in shares of Biodesix by 46.3% during the fourth quarter. Perkins Capital Management Inc. now owns 1,060,211 shares of the company’s stock worth $1,622,000 after acquiring an additional 335,429 shares during the last quarter. HighTower Advisors LLC grew its position in shares of Biodesix by 17.1% during the fourth quarter. HighTower Advisors LLC now owns 153,934 shares of the company’s stock worth $236,000 after acquiring an additional 22,500 shares during the last quarter. Finally, Stephens Inc. AR bought a new position in shares of Biodesix during the fourth quarter worth about $303,000. Institutional investors own 20.96% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.